The benefit of contrast-enhanced ultrasound in biopsies for focal liver lesions: a retrospective study of 820 cases

OBJECTIVE

This study compared the performance between ultrasound (US)- and contrast-enhanced US (CEUS)-guided liver biopsies and evaluated the benefit of CEUS in percutaneous biopsy for focal liver lesions (FLLs).

METHODS

We performed a retrospective study of 820 patients with FLLs, who underwent percutaneous liver biopsy in our center between 2017 and 2019. The patients were divided into two groups based on whether US (n = 362) or CEUS (n = 458) used before a biopsy. The two groups were compared based on specimen adequacy for pathological diagnosis and diagnostic accuracy of liver biopsy. Stratification analysis was performed based on lesion and protocol characteristics to provide detailed information for selecting the imaging guidance for biopsy.

RESULTS

Compared with the US group, the CEUS group yielded more acceptable samples (97.6% vs. 99.4%, p < 0.05) and improved diagnostic accuracy (92.6% vs. 96.4%, p < 0.05), and achieved better sensitivity (92.5% vs. 96.2%, p < 0.05) for liver biopsies, especially in FLLs ≥ 5 cm, heterogeneous hypoechoic FLLs, or FLLs with an obscure boundary. The CEUS group showed significantly higher accuracy compared with the US group pertaining to single-puncture biopsies (100% vs. 92.7%, p < 0.05) or biopsies with punctures ≤ 2 (97.6% vs. 94.3%, p < 0.05).

CONCLUSION

CEUS achieved an enhanced success rate for sampling and diagnostic accuracy of liver biopsies, especially in FLLs ≥ 5 cm, heterogeneous hypoechoic FLLs, or FLLs with an obscure boundary. CEUS can be used to decrease the number of punctures needed, which might increase the safety of liver biopsy.

KEY POINTS

• CEUS can help confirm an adequate biopsy site, increasing the sampling success rate and diagnostic accuracy of the liver biopsy. • CEUS can be used to decrease the number of punctures needed to improve the safety of liver biopsy. • It is recommended to use CEUS guidance for liver biopsies, especially with FLLs ≥ 5 cm, heterogeneous hypoechoic FLLs, or FLLs with an obscure boundary.

Combining conventional ultrasound and sonoelastography to predict axillary status after neoadjuvant chemotherapy for breast cancer

OBJECTIVE

To determine the ability of conventional ultrasound (US) combined with shear wave elastography (SWE) to reveal axillary status after neoadjuvant chemotherapy (NAC) in breast cancer patients.

METHODS

From September 2016 to December 2021, 201 patients with node-positive breast cancer who underwent NAC were enrolled in this prospective study. Conventional US features of axillary lymph nodes and SWE characteristics of breast lesions after NAC were analyzed. The diagnostic performances of US, SWE, and their combination were assessed using multivariate logistic regression and receiver operator characteristic curve (ROC) analyses.

RESULTS

The area under the ROC curve (AUC) for the ability of conventional US features to determine axillary status after NAC was 0.82, with a sensitivity of 85.23%, a specificity of 67.39%, and an accuracy of 76.11%. Shear wave velocity (SWV) displayed moderate performance for predicting axilla status after NAC with SWV_mean demonstrating an AUC of 0.85. Cortical thickness and shape of axillary nodes and SWV_mean of breast tumors were independently associated with axillary nodal metastasis after NAC. Compared to conventional US, the combination of conventional US of axillary lymph nodes with SWE of breast lesions achieved a significantly higher AUC (0.90 vs 0.82, p < 0.01, Delong's test) with a sensitivity of 87.50%, improved specificity of 82.61% and accuracy of 85.00%.

CONCLUSIONS

Breast SWE was independently associated with residual metastasis of axillary node after NAC in patients with initially diagnosed positive axilla. Combining SWE with conventional US showed good diagnostic performance for axillary node disease after NAC.

KEY POINTS

• Breast SWE can serve as a supplement to axilla US for the evaluation of the axilla after NAC. • The combination of axilla US with breast SWE may be a promising method to facilitate less-invasive treatment in patients receiving NAC.

Shear Wave Elastography Combined with Molecular Subtype in Early Predicting Response to Neoadjuvant Chemotherapy for Breast Cancer: A Prospective Case-control Study.. [DOI: 10.21203/rs.3.rs-600929/v1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0]

Background: This study was designed to investigate the performance of quantitative shear wave elastography (SWE) and the accuracy of SWE with the molecular subtype for early prediction of pathological response of breast cancer to neoadjuvant chemotherapy (NAC).Methods: In this prospective case-control study, 102 patients were screened from September 2016 to August 2020. Characteristics of conventional ultrasonography (US), SWE and contrast-enhanced magnetic resonance imaging (CE-MRI), were recorded, and the changes were compared to the pre-NAC baseline data. The pathological response was classified according to the Miller Payne grading system. Multivariate logistic regression was used to develop a predictive model for the response to NAC. Results: Significant differences related to changes in SWE characteristics of breast lesions between between pathological response groups were observed earlier than size on the conventional US and MRI images. According to the multivariate predictive model, the best parameter for predicting the pathological response after the first cycle of NAC was the molecular subtype of the tumor [area under the curve (AUC) = 0.83] with low sensitivity (66.04%). Better predictive performance was achieved when △AE/B and the molecular subtype were applied in combination after the second cycle of NAC (AUC = 0.92) with a higher sensitivity (86.79%). The predictive performance of molecular subtype combined with △AE/B and △SWVmean after the third and fourth cycles of NAC were improved (AUC = 0.94).Conclusion: The SWE can be an early predictor of the pathological response to NAC for breast cancer. The combination of SWE and the molecular subtype may be a preferred method for the clinical evaluation of NAC to facilitate the personalization of treatment regimens for breast cancer.